There is no approved medication for cocaine dependence. Not one — anywhere in the world.
For opioid dependence, methadone and buprenorphine exist and save lives. For alcohol, several medications are licensed. For cocaine and crack, effective pharmacotherapies are still lacking, and the effectiveness of behavioural and psychotherapeutic approaches alone is generally low. That gap is precisely why researchers have looked at ibogaine.
It is also where ibogaine has the strongest published evidence. The main peer-reviewed study from a Brazilian hospital programme was conducted largely in stimulant users, and reported 61% abstinent at follow-up.
There is one requirement that makes this harder than any other application, and it needs explaining honestly rather than buried further down.
You must stop before you start
To receive ibogaine for cocaine or crack dependence, you must already have stopped using — for at least four weeks, and in the published protocol for 30 to 60 days, with verification.
Most people react to this the same way, and the objection is entirely reasonable: I am coming to you because I cannot stop using cocaine, and you are asking me to stop using cocaine first.
The reason is cardiac, and it is specific rather than bureaucratic.
Stopping cocaine slows the heart rate. Ibogaine also slows the heart rate, and prolongs the QT interval. Give ibogaine to someone whose cardiovascular system is still in stimulant withdrawal and those effects compound — which is exactly the scenario in which serious complications occur. Research indicates that cocaine’s effect on the QT interval diminishes significantly after around a week of abstinence, and the protocol builds in a substantial margin beyond that.
Physician-led programmes regard requirements like this one as central to safe treatment. The rule is not there to filter customers. It is there because the alternative has killed people.
Why it is more achievable than it sounds
The requirement sounds impossible to someone in active dependence. In practice, it turns out to be the wrong intuition — for a reason worth understanding.
Cocaine and crack dependence rarely looks like continuous daily use. Most patients, asked honestly, have managed periods of two or three months without using at various points — not in a clinic, not with medication, on their own. The capacity is usually there. What has been missing is a reason for the abstinence to lead anywhere, and a date on the calendar.
That is what the preparation period supplies. It is not a waiting room; it is the first stage of treatment, with a defined endpoint.
Patients who cannot manage it at home are supported to complete it in a residential setting or clinic. Compliance is verified rather than assumed — weekly toxicology tests at home, often with family involvement, and a final test on the day of treatment.
There is a second benefit that clinicians consistently observe. Patients who arrive after four weeks clear of stimulants arrive with clear minds. They understand what is being explained to them, they engage with the psychotherapy, and they get considerably more out of the session itself.
What the evidence shows
This is where ibogaine’s published data is most directly applicable.
The 2014 retrospective study in the Journal of Psychopharmacology, co-authored by Dr. Rasmussen, reviewed 75 patients treated for alcohol, cannabis, cocaine and crack dependence — 72% polydrug users. It found:
- 61% abstinent at follow-up
- Median 5.5 months of abstinence after a single treatment
- Median 8.4 months among those treated more than once (statistically significant, p < 0.001)
- No serious adverse reactions and no fatalities
The authors concluded that ibogaine may be a safe and effective treatment for dependence on stimulants and other non-opiate drugs — the specific population studied.
The 2016 qualitative follow-up found that patients also reported reduced craving and improvements in personal relationships, quality of life and self-efficacy — outcomes that matter as much as consumption figures.
The caveats hold as they do everywhere in this field: no control group, a single programme, and retrospective design. But for stimulant dependence specifically, this is the best published evidence that exists — and it exists in a category where conventional medicine currently offers no pharmacological option at all.
What treatment involves
After the abstinence period and standard screening — ECG, blood tests, clinical and psychological assessment — treatment follows the usual protocol.
The patient arrives fasted. Dosing is by body weight: in current practice, around 15 mg/kg of pure ibogaine for stimulant-dependent patients, somewhat lower than the opioid dose. Effects begin roughly an hour after dosing.
Because there is no acute physical withdrawal to interrupt — unlike opioid cases — the session’s value for stimulant users lies in the craving reduction that follows and in the introspective phase, which most patients experience as vivid autobiographical material surfacing with unusual clarity.
Acute effects last around ten hours, with monitoring continuing for 24 to 48 hours.
Crack — the environment problem
Crack cocaine deserves its own paragraph, because clinicians consistently describe it as the hardest dependence they treat — and not for pharmacological reasons.
The difficulty is environmental. Crack use tends to be embedded in a setting that makes recovery structurally harder: the surroundings, the social network and the daily pattern all reinforce it, and returning to that environment after treatment undoes progress faster than in almost any other dependence.
This has a practical implication that no clinic can solve alone. For crack dependence, the plan for what happens after treatment — where the person lives, who they see, what fills the day — matters at least as much as the treatment itself. Programmes that do not ask those questions before admission are not treating the actual problem.
Is it appropriate for you?
Ibogaine for stimulant dependence is generally considered by people for whom rehab and therapy have not produced a durable result — and it is ruled out for others on cardiac, psychiatric or medication grounds. In responsible programmes, a significant share of applicants are found unsuitable.
The abstinence requirement is the practical hurdle, and it is worth discussing early rather than discovering later. If completing it at home is unrealistic, that changes which programmes make sense — and it is a solvable problem, not a disqualification.
Free and confidential. Our team reviews your case, including how to manage the abstinence period, and replies within 24 hours.